Table 1.
Demographic Characteristics of Patients with KRAS Mutation (N = 75)
| Factors | Number, n (%) |
|---|---|
| Gender | |
| Female | 17 (22.7%) |
| Male | 58 (77.3%) |
| Age, years | |
| <60 | 37 (49.3%) |
| ≥60 | 38 (50.7%) |
| Smoking history | |
| Yes | 59 (78.7%) |
| No | 16 (21.3%) |
| Performance score | |
| 0–2 | 61 (81.3%) |
| 3–4 | 14 (18.7%) |
| Histology | |
| Adenocarcinoma | 68 (90.7%) |
| *Nonadenocarcinoma | 7 (9.3%) |
| PD-L1 expression | |
| Yes | 21 (28%) |
| No | 9 (12%) |
| Unknown | 45 (60%) |
| TMB<10 mutations/Mb | |
| Yes | 9 (12%) |
| No | 5 (6.7%) |
| Unknown | 61 (81.3%) |
| Brain metastasis | |
| Yes | 18 (24%) |
| No | 56 (74.7%) |
| Unknown | 1 (1.3%) |
| Bone metastasis | |
| Yes | 33 (44%) |
| No | 42 (56%) |
| Pleural effusion | |
| Yes | 6 (8%) |
| No | 69 (92%) |
| Immune therapy | |
| Yes | 31 (41.3%) |
| No | 40 (53.3%) |
| Unknown | 4 (5.4%) |
| MEK inhibitor | |
| Yes | 9 (12%) |
| No | 66 (88%) |
| TKI | |
| Yes | 14 (18.7%) |
| No | 57 (76%) |
| Unknown | 4 (5.3%) |
| Angiogenesis inhibitors | |
| Yes | 18 (24%) |
| No | 57 (76%) |
| Brain radiation | |
| Yes | 12 (16%) |
| No | 51 (68%) |
| Unknown | 12 (16%) |
| 1st-line chemotherapy | |
| Taxanes-based | 7 (9.3%) |
| Pemetrexed-based | 51 (68%) |
| Gemcitabine-based | 3 (4%) |
| Other | 1 (1.3%) |
| No | 13 (17.4%) |
| 2nd-line chemotherapy | |
| Yes | 32 (42.7%) |
| No | 43 (57.3%) |
TMB, tumor mutation burden.
*Nonadenocarcinoma included two cases with adenosquamous carcinoma, two squamous carcinoma, three non–small cell lung cancer with unknown histologic subtype.